Foamix Announces New Foam Patent Approvals

Tuesday, November 13, 2007 General News J E 4
NESS ZIONA, Israel, November 13 Foamix Ltd., a leadingdeveloper of topical foam products for dermatology, gynecology and skin-care,has been awarded a New Zealand patent and four South African patents relatedto the Company's proprietary foam technology.

NZ Patent No. 540,166, entitled "Cosmetic and Pharmaceutical Foam", oneof the company's basic technology platform patents, was granted on October11, 2007. South African Patent No. ZA 2005/03298 with the same title wasgranted on August 30, 2006; ZA 2005/02180, titled "Penetrating PharmaceuticalFoam" was granted on June 28, 2006, and ZA 2005/02171 titled "Foam CarrierContaining Amphiphilic Copolymeric Gelling Agent" and ZA 2005/07017 titled"Cosmetic and Pharmaceutical Foam with Solid Matter" were both granted March28, 2007.

"These new patents and our anticipated future grants worldwide define ourserious intentions in this field," stated Dr. Dov Tamarkin, Chief ExecutiveOfficer of Foamix. "Our versatile foam technologies enable the development ofsuperior topical products, with enhanced functionality and ease-of-use,compared with traditional topical modalities. These patent grants areindicative of Foamix's ongoing progress in solidifying its intellectualproperty domain worldwide, for the benefit of Foamix and its industrialpartners."

In addition to the above, Foamix holds 3 issued US patents and has 57patents pending in the United States.

About Foamix:

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a specialtypharmaceutical company focused on the development of topical foam productsfor prescription, OTC and cosmetic applications. Foamix's state-of-the-artfoams provide controlled delivery of a variety of active ingredients. Foamixis a privately held company, whose business model is based on partnering withleading pharma companies to develop products utilizing its proprietary foamtechnologies. We currently collaborate with 8 pharmaceutical companies on 10projects in the development of proprietary dermatological and gynecologicalfoam drugs; and we have our own in-house pipeline of dermatological andgynecological drugs in foam presentation.

The company's development capabilities range from initial development offoam formulations to scale-up, GMP manufacturing, preclinical and clinicalstudies.For additional information please visit Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233,

SOURCE Foamix Ltd


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Michigan Hospitals Among Best in Nation on Two Tre...
Luxid(R) From TEMIS Receives Designed for EMC(R) D...